Last year, Biolinq secured $58 million in financing for FDA submission and to perform a clinical trial on its glucose sensor.
Company Description
Biolinq is a health technology company developing precision multi-analyte wearable biosensors for metabolic health. The company offers a wearable patch that evaluates glucose levels and provides insights into metabolic health for individuals with type 2 diabetes who are not on insulin.
Market
Type 2 Diabetes Management
Location
California,
USA
Coinvestors
AXA IM Alts, M Ventures, LifeSci Venture Partners, RiverVest Venture Partners, Hikma Ventures, Taisho Pharmaceutical, Features Capital, Aphelion Capital